ArticleJournal of the American Academy of Dermatology2020
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study.
Article in Journal of the American Academy of Dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 3 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Guideline
- A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa.Experimental dermatology · 2021Pooled it
- Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa.International journal of molecular sciences · 2020Pooled it
- IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.Experimental dermatology · 2022Trial
- Efficacy and safety of two interleukin-17 inhibitors (bimekizumab and secukinumab) in the management of hidradenitis suppurativa: a systematic review and meta-analysis of randomized controlled trials.Skin health and disease · 2026Review
- Symposium on Hidradenitis Suppurativa Advances 2025 Proceedings.Dermatology and therapy · 2026Review
- Hidradenitis Suppurativa and IL-17 Inhibitors: A Focus on Trials and Real-Life Data.Medicina (Kaunas, Lithuania) · 2026Review
- A Cross-Sectional Study on Relationships Between Depression and Anxiety in Hidradenitis Suppurativa Patients and Disease Severity, Subjective Symptoms and Quality of Life.Journal of clinical medicine · 2026Article
- Unique B- and plasma cell signature differentiates hidradenitis suppurativa from psoriasis and atopic dermatitis.Frontiers in immunology · 2026Article
- Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II.Dermatology and therapy · 2025Article
- Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Review
- Full spectrum town halls for hidradenitis suppurativa: A model for advancing clinician-patient-researcher engagement in clinical and translational research.Journal of clinical and translational science · 2025Article
- Data wobbles in hidradenitis suppurativa clinical trials and potential contributing factors: a retrospective review.International journal of women's dermatology · 2024Article
- Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis.Experimental dermatology · 2024Article
- Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa.Journal of the American Academy of Dermatology · 2024Article
- Diseases categorized as autoinflammatory keratinization diseases (AiKDs), and their pathologies and treatments.Nagoya journal of medical science · 2024Review
- Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment.Biomedicines · 2024Review
- A Critical Analysis of the FDA's Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity.Pharmaceuticals (Basel, Switzerland) · 2023Review
- IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa.Pharmaceutics · 2023Review
- Single-cell transcriptomics suggest distinct upstream drivers of IL-17A/F in hidradenitis versus psoriasis.The Journal of allergy and clinical immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundHidradenitis suppurativa is an autoinflammatory disorder of keratinization, with dysregulation of T helper type 17 cytokines. Brodalumab is a monoclonal antibody that targets the interleukin (IL) 17 receptor A receptor.
objectivesTo assess the safety and tolerability and clinical response at weeks 12 and 24 of brodalumab in moderate to severe HS. Ten participants with no history of inflammatory bowel disease were administered brodalumab 210 mg/1.5 mL subcutaneously at weeks 0, 1, and 2 and every 2 weeks thereafter until week 24. Participants were assessed for adverse events (grade 2/3 adverse events) and clinical response (Hidradenitis Suppurativa Clinical Response [HiSCR], Sartorius, International Hidradenitis Suppurativa Severity Scoring System [IHS4]), including ultrasonography and skin biopsies.
resultsAll 10 participants completed the study. No grade 2/3 adverse events associated with the use of brodalumab were reported. All patients (100%) achieved HiSCR, and 80% achieved IHS4 category change at week 12. HiSCR achievement occurred as early as week 2, likely due to the unique blockade of IL-17A, IL-17C, and IL-17F by brodalumab. Significant improvements were seen in pain, itch, quality of life, and depression.
conclusionsBrodalumab was well tolerated in this HS cohort, with no serious adverse events and improvement in clinical outcomes. Alterations in dose frequency may be required in those with advanced disease, which requires further exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.